Background: Multiple Sclerosis (MS) epidemiology in Italy is mainly based on population-based prevalence studies. Administrative data are an additional source of information, when available, in prevalence studies of chronic diseases such as MS. The aim of our study is to update the prevalence rate of MS in Tuscany (central Italy) as at 2011 using a validated case-finding algorithm based on administrative data. Methods: The prevalence was calculated using an algorithm based on the following administrative data: hospital discharge records, drug-dispensing records, disease-specific exemptions from copayment to health care, home and residential long-term care and inhabitant registry. To test algorithm sensitivity, we used a true-positive reference cohort of MS patients from the Tuscan MS register. To test algorithm specificity, we used another cohort of individuals who were presumably not affected by MS. Results: As at December 31, 2011, we identified 6,890 cases (4,738 females and 2,152 males) with a prevalence of 187.9 per 100,000. The sensitivity of algorithm was 98% and the specificity was 99.99%. Conclusions: We found a prevalence higher than the rates present in literature. Our algorithm, based on administrative data, can accurately identify MS patients; moreover, the resulting cohort is suitable to monitor disease care pathways.

Keywords:
Administrative data, Multiple sclerosis, Prevalence, Validation
1.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med 2000;343:938-952.
3.
Melcon MO, Correale J, Melcon CM: Is it time for a new global classification of multiple sclerosis? J Neurol Sci 2014;344:171-181.
4.
Bellantonio P, Iuliano G, Di Blasio F, Ruggieri S: Prevalence and incidence of multiple sclerosis in Campobasso (Molise region chieftown, southern Italy). Clin Neurol Neurosurg 2013;115:1806-1808.
6.
Puthenparampil M, Seppi D, Rinaldi F, Federle L, Calabrese M, Perini P, Gallo P; Multiple Sclerosis Epidemiology Veneto Study Group (MuSEV): Increased incidence of multiple sclerosis in the Veneto region, Italy. Mult Scler 2013;19:601-604.
7.
Solaro C, Ponzio M, Moran E, Tanganelli P, Pizio R, Ribizzi G, Venturi S, Mancardi GL, Battaglia MA: The changing face of multiple sclerosis: prevalence and incidence in an aging population. Mult Scler 2015;21:1244-1250.
8.
Granieri E, Monaldini C, De Gennaro R, Guttmann S, Volpini M, Stumpo M, Fazio P, Casetta I: Multiple sclerosis in the republic of San Marino: a prevalence and incidence study. Mult Scler 2008;14:325-329.
9.
Sardu C, Cocco E, Mereu A, Massa R, Cuccu A, Marrosu MG, Contu P: Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One 2012;7:e32487.
10.
Cocco E, Sardu C, Massa R, Mamusa E, Musu L, Ferrigno P, Melis M, Montomoli C, Ferretti V, Coghe G, Fenu G, Frau J, Lorefice L, Carboni N, Contu P, Marrosu MG: Epidemiology of multiple sclerosis in south-western Sardinia. Mult Scler 2011;17:1282-1289.
11.
Meucci G, Bianchi F, Rossi G: Indagine sulla prevalenza della sclerosi multipla nella USL n.17 del Valdarno inferiore; in 7th Italian Congress of Neuroepidemiology. Tipografia Umbra Perugia, 1992, p 35.
12.
Battaglia MA, Bezzini D, Ponzio M, Cipriani F: Mortality from Multiple Sclerosis in the Region of Tuscany (Central Italy). XLII Congress of the Italian Neurology Society, Torino, October 22-25, 2011.
13.
Govoni V, Casetta I, Granieri E, Vernonesi V, Malagù S, Tola MR, Paolino E, Fainardi E, Monetti VC, Aiello I: Mortality study on multiple sclerosis in the province of Ferrara, northern Italy, 1968 through 1989. Acta Neurol (Napoli) 1993;15:161-176.
14.
Grimaldi LM, Palmeri B, Salemi G, Giglia G, D'Amelio M, Grimaldi R, Vitello G, Ragonese P, Savettieri G: High prevalence and fast rising incidence of multiple sclerosis in Caltanissetta, Sicily, southern Italy. Neuroepidemiology 2007;28:28-32.
15.
Granieri E, Economou NT, De Gennaro R, Tola MR, Caniatti L, Govoni V, Fainardi E, Casetta I: Multiple sclerosis in the province of Ferrara: evidence for an increasing trend. J Neurol 2007;254:1642-1648.
16.
Nicoletti A, Patti F, Lo Fermo S, Sorbello V, Reggio E, Maimone D, Zappia M, Reggio A: Possible increasing risk of multiple sclerosis in Catania, Sicily. Neurology 2005;65:1259-1263.
17.
Mechati S, Peyro-St-Paul H: iMed: a new electronic database for monitoring patients with multiple sclerosis. Mult Scler 2001;7:S31.
18.
Trojano M, Paolicelli D, Lepore V, Fuiani A, Di Monte E, Pellegrini F, Russo P, Livrea P, Comi G; Italian MSDN Group: Italian Multiple Sclerosis Database Network. Neurol Sci 2006;27(suppl 5):S358-S361.
19.
Lix LM, Yogendran MS, Shaw SY, Burchill C, Metge C, Bond R: Population-based data sources for chronic disease surveillance. Chronic Dis Can 2008;29:31-38.
20.
Di Domenicantonio R, Cappai G, Arcà M, Agabiti N, Kohn A, Vernia P, Biancone L, Armuzzi A, Papi C, Davoli M: Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems. Dig Liver Dis 2014;46:777-782.
21.
Krysko KM, Ivers NM, Young J, O'Connor P, Tu K: Identifying individuals with multiple sclerosis in an electronic medical record. Mult Scler 2014;21:217-224.
22.
Brocco S, Visentin C, Fedeli U, Schievano E, Avogaro A, Andretta M, Avossa F, Spolaore P: Monitoring the occurrence of diabetes mellitus and its major complications: the combined use of different administrative databases. Cardiovasc Diabetol 2007;6:5.
23.
Cascini S, Agabiti N, Incalzi RA, Pinnarelli L, Mayer F, Arcà M, Fusco D, Davoli M: Pneumonia burden in elderly patients: a classification algorithm using administrative data. BMC Infect Dis 2013;13:559.
24.
Marrie RA, Yu N, Blanchard J, Leung S, Elliott L: The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010;74:465-471.
25.
Marrie RA, Yu BN, Leung S, Elliott L, Caetano P, Warren S, Wolfson C, Patten SB, Svenson LW, Tremlett H, Fisk J, Blanchard JF; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis: The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology 2013;40:85-92.
26.
Marrie RA, Yu BN, Leung S, Elliott L, Caetano P, Warren S, Wolfson C, Patten SB, Svenson LW, Tremlett H, Fisk J, Blanchard JF; CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis: Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler 2012;18:1310-1319.
27.
Marrie RA, Yu BN, Leung S, Elliott L, Warren S, Wolfson C, Tremlett H, Fisk J, Blanchard J: The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data. Neuroepidemiology 2012;39:135-142.
28.
Marrie RA, Fisk JD, Yu BN, Leung S, Elliott L, Caetano P, Warren S, Evans C, Wolfson C, Svenson LW, Tremlett H, Blanchard JF, Patten SB; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis: Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol 2013;13:16.
29.
Gini R, Francesconi P, Mazzaglia G, Cricelli I, Pasqua A, Gallina P, Brugaletta S, Donato D, Donatini A, Marini A, Zocchetti C, Cricelli C, Damiani G, Bellentani M, Sturkenboom MC, Schuemie MJ: Chronic disease prevalence from Italian administrative databases in the VALORE project: a validation through comparison of population estimates with general practice databases and national survey. BMC Public Health 2013;13:15.
30.
Baldacci F, Policardo L, Rossi S, Ulivelli M, Ramat S, Grassi E, Palumbo P, Giovannelli F, Cincotta M, Ceravolo R, Sorbi S, Francesconi P, Bonuccelli U: Reliability of administrative data for the identification of Parkinson's disease cohorts. Neurol Sci 2015;36:783-786.
32.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
33.
Granberg T, Martola J, Kristoffersen-Wiberg M, Aspelin P, Fredrikson S: Radiologically isolated syndrome - incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. Mult Scler 2013;19:271-280.
34.
Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, Keegan BM, Donlon S, Hua le H, Vidal-Jordana A, Montalban X, Rovira A, Tintoré M, Amato MP, Brochet B, de Seze J, Brassat D, Vermersch P, De Stefano N, Sormani MP, Pelletier D, Lebrun C; Radiologically Isolated Syndrome Consortium (RISC); Club Francophone de la Sclérose en Plaques (CFSEP): Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One 2014;9:e90509.
35.
Tedeholm H, Skoog B, Lisovskaja V, Runmarker B, Nerman O, Andersen O: The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset. J Neurol 2015;262:1148-1163.
36.
Bottacchi E, Corso G, Tosi P, Morosini MV, De Filippis G, Santoni L, Furneri G, Negrini C: The cost of first-ever stroke in Valle d'Aosta, Italy: linking clinical registries and administrative data. BMC Health Serv Res 2012;12:372.
37.
Leal T, Reychler G, Mailleux P, Gigi J, Godding V, Lebecque P: A specific database for providing local and national level of integration of clinical data in cystic fibrosis. J Cyst Fibros 2007;6:187-193.
38.
Myers DL, Burke KC, Burke JD Jr, Culp KS: An integrated data warehouse system: development, implementation, and early outcomes. Manag Care Interface 2000;13:68-72.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.